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The signs of metabolic syndrome following chronic excessive macronutrient intake include body weight gain, excess visceral
adipose deposition, hyperglycaemia, glucose and insulin intolerances, hypertension, dyslipidaemia, endothelial damage, cardiovas-
cular hypertrophy, inflammation, ventricular contractile dysfunction, fibrosis, and fatty liver disease. Recent studies show increased
activity of soluble epoxide hydrolase (sEH) during obesity and metabolic dysfunction. We have tested whether sEH inhibition
has therapeutic potential in a rat model of diet-induced metabolic syndrome. In these high-carbohydrate, high-fat-fed rats,
chronic oral treatment with trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid (t-AUCB), a potent sEH inhibitor,
alleviated the signs of metabolic syndrome in vivo including glucose, insulin, and lipid abnormalities, changes in pancreatic
structure, increased systolic blood pressure, cardiovascular structural and functional abnormalities, and structural and functional
changes in the liver. The present study describes the pharmacological responses to this selective sEH inhibitor in rats with the signs
of diet-induced metabolic syndrome.
1. Introduction
Chronic metabolic dysfunction leading to obesity and dia-
betes represents a major challenge to health worldwide [1, 2].
Lifestyle changes such as an excessive caloric intake are indi-
cated as important factors in initiating obesity and the as-
sociated metabolic and cardiovascular disorders [1–4]. This
prevalent human condition is now collectively referred to as
“metabolic syndrome” [3, 4]. Leading definitions of meta-
bolic syndrome differ mainly in threshold values but in
general emphasise the clustering of abdominal obesity, dy-
slipidaemia, hyperglycaemia, a prothrombotic state, and
hypertension in increasing an individual’s risk of developing
type II diabetes mellitus, insulin resistance, and cardio-
vascular disease earlier in adult life [5–10]. This syndrome
is associated with complications throughout the body such
as excessive visceral fat deposition, hypertension, endo-
thelial damage, cardiovascular hypertrophy, inflammation,
atherosclerosis, ventricular contractile dysfunction, fibrosis
and fatty liver disease [5, 8]. Identifying adequate therapeutic
and preventive alternatives for this multifactorial syndrome
has so far been challenging.
Arachidonic acid is the precursor of the eicosanoid family
of signalling lipid mediators that modulate immune and in-
flammatory responses in the body [1, 11]. They are meta-
bolised by cyclooxygenases, lipoxygenases, and cytochrome
P450 monooxygenases to form biologically active products,
including prostaglandins, leukotrienes, epoxyeicosatrienoic
acids (EETs), and hydroxyeicosatetraenoic acids [1, 12, 13].
Pharmacological manipulation of the cyclooxygenase and
lipoxygenase pathways improves adiposity and insulin sensi-
tivity in humans and animal models [1, 14–16]. The cyto-
chrome P450 enzymes generate EETs by catalysing the
epoxidation of arachidonic acid [17]. EETs are endotheli-
um-derived hyperpolarising factors that protect cells from
ischaemic injury and possess anti-inflammatory responses
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in canine and rodent disease models [17]. These endogenous
lipid mediators are converted into inactive diols by soluble
epoxide hydrolase (sEH), and so inhibiting this enzyme
would be expected to enhance the stability and therapeutic
actions of EETs [17]. Orally active and selective sEH
inhibitors that are based on 1,3-disubstituted urea and to a
lesser extent amides and carbamates have been developed
for chronic in vivo studies; in vivo these derivatives have
proven to be antihypertensive and anti-inflammatory and
protect the brain, heart, and kidney from damage [17].
Further, these derivatives produced analgesic responses in
pain models [18].
Although it is well established that sEH inhibition im-
proves cardiovascular and renal diseases [19–21], the thera-
peutic potential of sEH inhibition in diet-induced metabolic
syndrome is still largely unknown [17]. To test the hypoth-
esis that EETs are important in metabolic control, this
study has evaluated trans-4-[4-(3-adamantan-1-ylureido)-
cyclohexyloxy]-benzoic acid (t-AUCB) (Figure 1), a potent
sEH inhibitor [22] with greater in vivo metabolic stability
than many other sEH inhibitors [22], in a rat model of diet-
induced metabolic syndrome. We have investigated whether
chronic oral treatment with t-AUCB improved adiposity,
control of blood glucose, insulin, and lipid homeostasis and
the associated structural and functional changes in meta-
bolic, liver, and cardiovascular systems induced by high-
carbohydrate, high-fat feeding in rats.
2. Materials and Methods
2.1. Diet-Induced Metabolic Syndrome in Rats. All experi-
mental protocols were approved by the University of Queens-
land Animal Experimentation Ethics Committee, under the
guidelines of the National Health and Medical Research
Council of Australia. Male Wistar rats (8-9 weeks old)
were obtained from The University of Queensland Biological
Resources facility. The rats were randomly divided into four
experimental groups and were fed with either corn starch diet
(CS; n = 24) or high-carbohydrate high-fat diet (HCHF;
n = 24) for 16 weeks. The CS diet contained 570 g corn
starch, 155 g powdered rat food (Specialty feeds, Glen Forest,
WA, Australia), 25 g Hubble, Mendel, and Wakeman (HMW)
salt mixture, and 250 g water per kilogram of food. HCHF
diet contained 175 g fructose, 395 g sweetened condensed
milk, 200 g beef tallow, 155 g powdered rat food, 25 g HMW
salt mixture, and 50 g water per kilogram of food [23]. In
addition, the drinking water for the HCHF group was sup-
plemented with 25% fructose [23]. 12 rats from each CS and
HCHF group were randomised into t-AUCB treatment at 8
weeks. Rats were given ad libitum access to food and water
and were individually housed in a temperature-controlled
12 hours light-dark conditions. t-AUCB was administered in
the drinking water in both CS and HCHF groups with the
final dose calculated from daily drinking water consumption.
Final doses of t-AUCB were 1.4 mg/Kg/day in CS-fed and
0.95 mg/Kg/day in HCHF-fed rats. t-AUCB was dissolved
in 10 mL of distilled water made slightly basic with sodium
hydroxide and then diluted to 1 L with distilled water.
2.2. Physiological Parameters. Body weight and food and wa-
ter intakes were measured daily. Oral glucose tolerance and
clearance tests have been previously described [23, 24]. Plas-
ma lipids and enzyme concentrations were measured by the
Veterinary Pathology Service of The University of Queens-
land, QLD, Australia [23, 24]. Systolic blood pressure of rats
was measured as previously described [23–26].
2.3. Body Composition Measurements. Dual-energy X-ray ab-
sorptiometric (DXA) measurements were performed on the
rats after 16 weeks of feeding (2 days before rats were eu-
thanised for pathophysiological assessments) as previously
described [23].
2.4. Experimental Protocol. Eight rats from each group were
used for isolated Langendorff ’s preparations and vascular
reactivity studies, and four rats per group were taken exclu-
sively for histopathological analysis. For terminal experi-
ments, rats were euthanised with Lethabarb (pentobarbitone
sodium, 100 mg/kg, i.p.; Virbac, Peakhurst, NSW, Australia).
After euthanasia, heparin (200 IU; Sigma-Aldrich Australia,
Sydney, NSW, Australia) was injected through the right
femoral vein. The abdomen was then opened, and blood
(∼6 mL) was withdrawn from the abdominal aorta and col-
lected into heparinised tubes and centrifuged at 5,000×g for
15 minutes to obtain plasma. Plasma was stored at−20◦C for
further characterisation. Hearts were removed from rats for
isolated Langendorff ’s preparation, and thoracic aortic rings
were used for vascular reactivity studies as described below
[25]. Liver, kidneys, and fat pads were removed from these
rats and weighed. After perfusion studies, right ventricles
from the hearts were removed and weighed whereas the left
ventricle was weighed with septum. Weights of these organs
were normalised relative to the tibial length at the time of
removal (expressed as tissue weight in mg/mm tibial length)
[23]. Heart, liver, kidney, and pancreas from the rats used
for histopathological analysis were removed and fixed in
appropriate solutions [23].
2.5. Structural Changes in Liver, Pancreas, and Adipose Tissue.
Liver and pancreas were fixed with 10% neutral buffered for-
malin for three days. These tissue samples were dehydrated
and then embedded in paraffin wax. Thin sections (5 μm)
of these tissues were cut and stained with Wright’s staining
for determination of inflammatory cell infiltration and for
determining the fat vacuoles in liver. Liver sections were also
stained with Milligan’s stain to determine collagen depo-
sition and to determine fat droplets. Routine histological
stains used were Wright’s for general histology and Milligan’s
for assessment of collagen deposition. Milligan’s stained
slides were visualised using a Nikon Eclipse 50i microscope
(Kanagawa, Japan) fitted with a DSFi1 camera, and images
were captured directly digitally (magnification ×200). Pan-
creatic sections were stained with aldehyde fuchsin stain-
ing following pretreatment with potassium permanganate
(0.5%) and haematoxylin and eosin staining to determine
infiltration of inflammatory cells. After staining, tissues were
mounted, and pictures were taken with a Zeiss Microscope
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(magnification ×40 for haematoxylin and eosin and ×20
for aldehyde fuchsin, oil red “O”, and Milligan’s stain). Islet
area was quantified using NIH image J software (National
Institute of Health, USA). Results are presented as mean ±
SEM of the area of view. α and β cells in 12 islets were counted
in each rat using NIH-image J software. Numbers of these
cells are presented as mean ± SEM per islet [23]. Adipose
tissue was fixed with 10% neutral buffered formalin for 1
day. Cryostat sections were prepared of this tissue in OCT as
per normal histological procedures. Thick sections (40 μm)
of these tissues were cut and stained with Wright’s staining
for determination of inflammatory cell infiltration.
2.6. Cardiovascular Structure and Function. Echocardio-
graphic examination was performed as previously described
in all rats after 16 weeks [23, 27]. The isolated Langendorff ’s
heart preparation was used to assess left ventricular function
of the rats in all the groups as in previous studies [23, 25].
End diastolic pressures were obtained from 0 mmHg up to
30 mmHg for the calculation of diastolic stiffness constant (κ,
dimensionless) as described in previous studies [23, 24, 26].
Thoracic aortic rings (4 mm in length) were suspended in
an organ bath filled with Tyrode’s physiological salt solution
bubbled with 95% O2–5% CO2, maintained at 35◦C, and
allowed to stabilise at a resting tension of 10 mN. Cumulative
concentration-response curves (contraction or relaxation)
were obtained as in previous studies [25, 26]. Hearts were
processed by two different procedures for histopathological
studies as in previous studies [23, 25, 26].
2.7. Statistical Analysis. All data are presented as mean ±
SEM. Differences between the groups were determined by
one-way analysis of variance. Statistically significant vari-
ables were treated with the Neuman-Keuls post hoc test to
compare all the groups of animals. For body weight data,
Student’s t-tests were performed. All statistical analyses were
performed using Graph Pad Prism version 5 for Windows
(San Diego, Calif, USA) with a P value of <0.05 considered
as statistically significant.
3. Results
3.1. HCHF Diet Induces Signs of the Metabolic Syndrome.
Young male Wistar rats fed HCHF diet showed progressive
increases in body weight, abdominal fat deposition, and
whole body fat mass along with impaired glucose toler-
ance, plasma lipid abnormalities, hyperinsulinaemia, and
increased plasma leptin concentrations [23]. Cardiovascular
changes included increased systolic blood pressure and
endothelial dysfunction together with inflammation, fibro-
sis, hypertrophy, and increased stiffness of the left ventricle
of the heart [23]. The liver showed increased wet weight, fat
deposition, inflammation, and fibrosis with increased plasma
activity of liver enzymes. The pancreas showed increased islet
size. Treatment with t-AUCB from week 8 to 16 attenuated
the metabolic, liver, and cardiovascular abnormalities, out-
lined below, but did not affect the increased body weight,
abdominal fat deposition, and whole body fat mass (Table 1).
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Figure 1: Chemical structure of the potent sEH inhibitor, trans-
4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid (t-
AUCB).
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Figure 2: Plasma glucose concentrations following oral gavage of
glucose (2 g/kg) recorded after 16 weeks for rats fed with corn starch
(CS), high carbohydrate high fat (HCHF), corn starch with t-AUCB
(CS + t-AUCB), and high carbohydrate high fat with t-AUCB
(HCHF + t-AUCB). ∗P < 0.05 versus CS-fed rats; ∗∗P < 0.05 versus
HCHF-fed rats.
3.2. Treatment with t-AUCB Attenuated Metabolic Abnor-
malities. Overnight fasting blood glucose concentrations
did not differ among the experimental groups. Following
oral glucose loading, blood glucose concentrations in CS-
fed rats increased after 30 mins then decreased rapidly and
returned to fasting glucose concentrations at 120 mins after
glucose loading (Figure 2). In HCHF-fed rats, blood glucose
concentrations decreased much more slowly and were higher
at 120 mins after glucose loading compared to CS-fed rats,
suggesting glucose intolerance (Figure 2). Blood glucose
concentrations at both 4-hour fasting and 75 mins after
intraperitoneal administration of insulin were much higher
in HCHF-fed rats compared to CS-fed rats suggesting insulin
intolerance (Figure 3). Both of the above features were atten-
uated with t-AUCB treatment in HCHF-fed rats (Figures
2 and 3). Plasma concentrations of insulin were increased
with HCHF diet after 16 weeks in comparison to CS diet
(Table 1). Plasma leptin concentrations did not increase with
the HCHF diet compared to CS diet at 16 weeks (Table 1).
t-AUCB did not prevent the increased insulin concentrations
in HCHF-fed rats but further increased insulin concentra-
tions in CS-treated rats (Table 1). Further, plasma concen-
trations of NEFA, total cholesterol, and triglycerides were
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Table 1: Physiological parameters of CS-, HCHF-, CS + t-AUCB-, HCHF + t-AUCB-treated rats. ∗P < 0.05 versus CS-fed rats; ∗∗P < 0.05
versus HCHF-fed rats.
Parameter CS (16 weeks) HCHF (16 weeks)
CS + t-AUCB
(16 weeks)
HCHF + t-AUCB
(16 weeks)
Body weight @ week 16 (g)
422 ± 6
(n = 6)
515.8 ± 11.9
(n = 6)
415 ± 6
(n = 6)
515.7 ± 13
(n = 6)
Abdominal fat deposition
(mg/mm tibial length)
401 ± 56
(n = 6)
746 ± 67∗
(n = 6)
270 ± 38
(n = 6)
674 ± 99∗
(n = 6)
Total fat mass (g)
56 ± 5
(n = 6)
139.4 ± 16∗
(n = 6)
46.7 ± 8
(n = 6)
154.3 ± 19∗
(n = 6)
Heart rate (bpm)
249 ± 9
(n = 6)
251 ± 21
(n = 6)
262 ± 13
(n = 6)
265 ± 8
(n = 6)
LVIDd (mm)
6.73 ± 0.2
(n = 6)
7.54 ± 0.18∗
(n = 6)
6.8 ± 0.2∗∗
(n = 6)
6.8 ± 0.2∗∗
(n = 6)
LVPWd (mm)
1.69 ± 0.1
(n = 6)
1.95 ± 0.1
(n = 6)
1.69 ± 0.08
(n = 6)
1.9 ± 0.1
(n = 6)
LVIDs (mm)
3.9 ± 0.3
(n = 6)
4.9 ± 0.2∗
(n = 6)
3.6 ± 0.2∗∗
(n = 6)
4.2 ± 0.2∗∗
(n = 6)
E/A ratio
1.6 ± 0.1
(n = 6)
1.2 ± 0.1∗
(n = 6)
2.0 ± 0.2∗∗
(n = 6)
1.5 ± 0.04∗∗
(n = 6)
Ejection fraction (%)
79 ± 4
(n = 6)
72 ± 2
(n = 6)
85 ± 2∗∗
(n = 6)
76 ± 3
(n = 6)
Cardiac output (mL/min)
63.4 ± 6.4
(n = 6)
83.8 ± 9
(n = 6)
81.8 ± 10
(n = 6)
72.2 ± 7
(n = 6)
Estimated LV mass (g)
0.74 ± 0.05
(n = 6)
1.0 ± 0.05∗
(n = 6)
0.77 ± 0.05∗∗
(n = 6)
0.84 ± 0.04∗∗
(n = 6)
Diastolic stiffness constant (κ)
20.5 ± 1.9
(n = 6)
28.9 ± 1∗
(n = 6)
22.8 ± 0.4∗∗
(n = 6)
20.1 ± 0.1∗∗
(n = 6)
Plasma insulin concentrations
2.2 ± 0.4
(n = 5)
4.2 ± 0.3∗
(n = 5)
4.7 ± 1.1∗
(n = 5)
5.2 ± 1∗
(n = 5)
Plasma leptin concentrations
6.8 ± 0.86
(n = 5)
8.6 ± 1.1
(n = 5)
6.9 ± 0.8
(n = 5)
9.7 ± 0.5
(n = 5)
Plasma ALT activity, U/L
37 ± 0.6
(n = 5)
59.6 ± 0.3∗
(n = 5)
52.3 ± 2∗
(n = 5)
49.4 ± 3.2∗
(n = 5)
Plasma AST activity, U/L
73.2 ± 5.6
(n = 5)
105.3 ± 9∗
(n = 5)
68.2 ± 3.2∗∗
(n = 5)
69.7 ± 5.7∗∗
(n = 5)
Plasma ALP activity, U/L
174 ± 19
(n = 5)
251 ± 21∗
(n = 5)
192 ± 11∗∗
(n = 5)
274 ± 29∗
(n = 5)
Plasma LDH activity, U/L
204 ± 23
(n = 5)
497 ± 14∗
(n = 5)
180 ± 56∗∗
(n = 5)
184 ± 26∗∗
(n = 5)
LV + septum (mg/mm tibial length)
18.9 ± 0.9
(n = 6)
21.8 ± 1.1
(n = 6)
20.3 ± 1.5
(n = 6)
20.5 ± 0.8
(n = 6)
Right ventricle (mg/mm tibial length)
4.14 ± 0.3
(n = 6)
4.48 ± 0.3
(n = 6)
3.7 ± 0.2
(n = 6)
4.4 ± 0.3
(n = 6)
Liver (mg/mm tibial length)
234 ± 14
(n = 6)
287 ± 12∗
(n = 6)
264 ± 15
(n = 6)
292 ± 19∗
(n = 6)
Islets as % area of pancreas
6.2 ± 1.4
(n = 6)
15.3 ± 1.5
(n = 6)
5.2 ± 0.1
(n = 6)
16.7 ± 1.3
(n = 6)
Number of α cells/islet
16.9 ± 0.5
(n = 6)
39.3 ± 1.2
(n = 6)
22.4 ± 1.9
(n = 6)
38.6 ± 1.4
(n = 6)
Number of β cells/islet
72.3 ± 2.8
(n = 6)
124.7 ± 7.2
(n = 6)
117.1 ± 4.1
(n = 6)
149.8 ± 6.3
(n = 6)
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Figure 3: Plasma glucose concentrations following 0.3 U/Kg insulin
i.p. dose after 16 weeks for rats fed with corn starch (CS), high car-
bohydrate high fat (HCHF), corn starch with t-AUCB (CS + t-
AUCB), and high carbohydrate high fat with t-AUCB (HCHF + t-
AUCB). ∗P < 0.05 versus CS-fed rats; ∗∗P < 0.05 versus HCHF-fed
rats.
elevated with HCHF feeding compared to CS-fed controls
(Figure 4). Treatment with t-AUCB completely normalised
these increased NEFA and total cholesterol concentrations
in HCHF-fed rats (Figure 4). In CS-fed rats treated with t-
AUCB, there was a further reduction in NEFA concentrations
compared to control rats (Figure 4). There was no change
in increased plasma triglycerides with t-AUCB treatment in
HCHF-fed rats (Figure 4).
3.3. Structure and Function of Liver, Pancreas, and Adipose
Tissue Are Moderated by t-AUCB. Postmortem liver weights
(normalised to tibial length) from HCHF-fed rats were in-
creased compared to CS-fed rats (Table 1). Treatment with
t-AUCB did not prevent this organ’s hypertrophy induced
by HCHF feeding (Table 1). Histological analysis of liver
samples showed HCHF diet-fed rats to have increased
infiltration of inflammatory cells and increased deposition
of collagen around the blood vessels compared to CS diet-
fed rats (Figure 5). HCHF diet-fed rats showed deposition
of fat droplets in liver, which were rarely observed in livers
from CS diet-fed rats (Figure 5). Also, the size of fat
vacuoles was larger in HCHF diet-fed rats (Figure 5). t-
AUCB treatment attenuated the mild steatosis and increased
hypertrophy and vacuole size seen in HCHF-fed rats with-
out affecting the increased inflammatory cell infiltration
(Figure 5). HCHF diet resulted in increased plasma activ-
ity of AST, ALT, ALP, and LDH compared to CS diet-
fed rats indicating liver cell damage (Table 1). Treatment
with t-AUCB attenuated the increased AST and LDH
concentrations but not the ALT and ALP concentrations
(Table 1).
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Figure 4: Plasma lipid concentrations after 16 weeks for rats fed
with corn starch (CS), high carbohydrate high fat (HCHF), corn
starch with t-AUCB (CS + t-AUCB), and high carbohydrate high
fat with t-AUCB (HCHF + t-AUCB). ∗P < 0.05 versus CS-fed rats;
∗∗P < 0.05 versus HCHF-fed rats.
The pancreas from HCHF diet-fed rats showed an in-
creased number of inflammatory cells (Figure 5) with in-
creased size of islets of Langerhans compared with CS diet-
fed rats. Numbers of both α and β cells were also increased in
HCHF diet-fed rats compared to CS diet-fed rats. Treatment
with t-AUCB did not change the islets size in CS- or in
HCHF-fed rats. t-AUCB treatment increased the number of
both α and β cells in CS diet-fed rats but only increased
β-cell numbers in HCHF-fed rats (Figure 6). Histological
analysis of the adipose tissue samples showed increased
infiltration of immune inflammatory cells with HCHF feed-
ing at 16 weeks compared to CS-fed rats (Figure 7). Treat-
ment with t-AUCB did not reduce this increased infiltration
(Figure 7).
3.4. Treatment with t-AUCB Attenuated Changes in Cardio-
vascular Structure and Function. Heart rate did not vary
among the experimental groups (Table 1). Systolic blood pre-
ssure in HCHF-fed rats increased sharply at week 4 and
remained elevated until the end of the study protocol
compared to CS-fed rats (Figure 8). Treatment with t-AUCB
completely reversed the increased systolic blood pressure in
HCHF-fed rats at 16 weeks (Figure 8). Echocardiographic
assessment of HCHF-fed rats showed ventricular dilata-
tion (increased left ventricular end diastolic dimensions),
increased systolic volume, and increased estimated left ven-
tricular mass (Table 1). Treatment with t-AUCB from week 8
to week 16 attenuated all these structural changes in HCHF-
fed rats (Table 1).
Many inflammatory cells were observed in the left ventricle
of HCHF-fed rats, whereas the number of inflammatory cells
in the left ventricle of CS-fed rats was very low (Figure 9).
Treatment with t-AUCB, in general, did not prevent this
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Figure 5: Structural changes and mild inflammation in the liver after 16 weeks for rats fed with corn starch (CS) (a) and (e), high
carbohydrate high fat (HCHF) (b) and (f), corn starch with t-AUCB (CS + t-AUCB) (c) and (g), and high carbohydrate high fat with
t-AUCB (HCHF + t-AUCB) (d) and (h).
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 6: Structural changes in the pancreatic islets of Langerhans after 16 weeks for rats fed with corn starch (CS) (a) and (e), high
carbohydrate high fat (HCHF) (b) and (f), corn starch with t-AUCB (CS + t-AUCB) (c) and (g), and high carbohydrate high fat with
t-AUCB (HCHF) (d), (h), Magnification 20x.
increased infiltration of inflammatory cells but selectively
prevented increased mast cells into the left ventricle in
HCHF-fed rats. Interstitial collagen contents in left ventricle
were increased in HCHF-fed rats compared with CS-fed
rats (Figure 9). Treatment with t-AUCB attenuated this
increase in interstitial collagen deposition in HCHF-fed rats
(Figure 9). The isolated Langendorff ’s heart preparation
showed increased diastolic stiffness in HCHF-fed rats at 16
weeks compared to CS-fed rats (Table 1). Treatment with
t-AUCB from week 8 to week 16 completely reversed this
increase in left ventricular diastolic stiffness in HCHF-fed
rats (Table 1).
Lastly, organ bath studies showed no change in vascu-
lar responses to noradrenaline (constriction) and sodium
nitroprusside (relaxation) among all treatment groups
(Figure 10). In contrast, HCHF-fed rats showed pronounced
endothelial dysfunction, seen as reduced vascular relaxation
responses to acetylcholine compared to both CS-fed rats
(Figure 10). Treatment with t-AUCB attenuated this de-
creased response to acetylcholine (Figure 10).
Experimental Diabetes Research 7
100 μm
(a)
100 μm
(b)
100 μm
(c)
100 μm
(d)
Figure 7: Structural changes and mild inflammation in the adipose tissue after 16 weeks for rats fed with corn starch (CS) (a), high
carbohydrate high fat (HCHF) (b), corn starch with t-AUCB (CS + t-AUCB) (c), and high carbohydrate high fat with t-AUCB (HCHF +
t-AUCB) (d).
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Figure 8: Systolic blood pressure measurements for rats fed with
corn starch (CS), high carbohydrate high fat (HCHF), corn starch
with t-AUCB (CS + t-AUCB), and high carbohydrate high fat with
t-AUCB (HCHF + t-AUCB). ∗P < 0.05 versus CS-fed rats; ∗∗P <
0.05 versus HCHF-fed rats.
4. Discussion
The signs of metabolic syndrome following chronic excessive
macronutrient intake include body weight gain, excess vis-
ceral adipose deposition, hyperglycaemia, glucose and in-
sulin intolerances, hypertension, dyslipidaemia, endothelial
damage, cardiovascular hypertrophy, inflammation, ventric-
ular contractile dysfunction, fibrosis, and fatty liver disease.
Although it is well recognised that the inhibition of sEH
lowers blood pressure in different rat models [19, 21, 28], the
therapeutic potential of sEH inhibition in the control of diet-
induced adiposity, metabolic and cardiovascular dysfunction
are unknown. In this study, we show that sEH inhibition
has therapeutic potential in the control of diet-induced
prediabetes and metabolic syndrome. We report that chronic
oral treatment with t-AUCB (∼1 mg/kg/day), a potent
sEH inhibitor [22], alleviated the symptoms of metabolic
syndrome in vivo including glucose, insulin and lipid abnor-
malities, changes in pancreatic structure, increased systolic
blood pressure, and cardiovascular and liver structural and
functional abnormalities induced by chronic high-carbohy-
drate high-fat feeding in rats.
Clinical, animal and in vitro studies support links be-
tween obesity, insulin resistance, type II diabetes, metabolic
dysfunction, and inflammation. Anti-inflammatory agents
such as NSAIDs, salicylates, and aspirin reduce the severity
of metabolic dysfunction [1, 2]. Local adipose tissue inflam-
mation and inflammatory lipid mediators including EETs
have been suggested to play important roles in regulating
adipocyte function and metabolic homeostasis [1]. A recent
study reported that sEH mRNA and protein concentrations
in adipose tissue did not differ between normal- and fat-fed
animals, but total adipose sEH activity was increased in obese
mice, with a large increase during maturation of adipocytes
[29]. Given the involvement of sEH in inflammation and also
the increased activity of sEH during obesity and metabolic
dysfunction, we hypothesised that increasing EET concentra-
tions by sEH inhibition may be important in controlling obe-
sity and the symptoms of the metabolic syndrome. Chronic
oral treatment with t-AUCB improved metabolic and car-
diovascular symptoms but did not alter body weight gain,
excess visceral adipose deposition, or infiltration of immune
inflammatory cells into the adipose tissue compared to
untreated rats. This implies that t-AUCB acts to increase the
anti-inflammatory EETs as metabolites of arachidonate pro-
duced by phospholipase A2 from inflammatory cells, rather
than preventing infiltration of these immune inflammatory
cells. It is well accepted that inhibition of sEH increases EET
concentrations by decreasing their conversion into inactive
diols (DHETs) [20]. Further, t-AUCB treatment reduces the
production of DHETs and increases the ratios of EETs to
DHETs in the plasma of lipopolysaccharide-treated mice
[22]. Similarly, sEH knock-out mice have higher plasma
ratios of EETs to DHETs than wild-type mice [30]. Thus, it is
likely that sEH inhibition by t-AUCB may prevent adipocyte
dysfunction downstream of immune inflammatory cell infil-
tration without affecting adiposity [1].
Further, changes in glucose, insulin, and lipid homeosta-
sis are characteristic of insulin resistance, type II diabetes,
and metabolic syndrome. There is growing incidental evi-
dence to suggest the involvement of sEH in glucose, insulin,
and lipid abnormalities. CYP2J protein, which generates
EETs, is expressed in human and rat pancreatic tissues where
8 Experimental Diabetes Research
50 µm
(a)
50 µm
(b)
50 µm
(c)
50 µm
(d)
200µm
(e)
200µm
(f)
200µm
(g)
200µm
(h)
200µm
(i)
200µm
(j)
(k)
+
F
H
C
H
t
B
C
U
A-
+
S
C
t
B
C
U
A-
F
H
C
H
S
C
0
4
8
12
16
20
24)
%(
negalloclaititsret
nI
∗
∗∗
Figure 9: Inflammation and fibrosis in the heart. Representative images of left ventricular interstitial collagen deposition stained in
picrosirius red staining (×40) after 16 weeks in CS (a), HCHF (b), CS + t-AUCB (c), HCHF + t-AUCB (d). Wright’s staining of LV of
the heart (×40) showing infiltration of inflammatory cells after 16 weeks in CS (e), HCHF (f), CS + t-AUCB (g), HCHF + t-AUCB (h).
Wright’s staining of LV of the heart (×100) showing infiltration of mast cells after 16 weeks in HCHF (i), HCHF + t-AUCB (j). Summary
data of left ventricular interstitial collagen deposition (k) after 16 weeks in CS, HCHF, CS + t-AUCB, HCHF + t-AUCB. ∗P < 0.05 versus
CS-fed rats, ∗∗P < 0.05 versus HCHF-fed rats.
significant amounts of endogenous EETs have been detected
[31]. Also, EETs are potent mediators of insulin release in
isolated rat islets [32]. In this study, we investigated whether
t-AUCB treatment improves glucose and insulin intolerances
and elevated plasma lipids induced by high-carbohydrate
high-fat feeding. Oral glucose and intraperitoneal insulin tol-
erance tests showed improved tolerance to both glucose and
insulin in rats treated with t-AUCB compared to untreated
ones. A recent study assessed the role of sEH in glucose and
insulin homeostasis in streptozotocin- (STZ-) treated mice
using both sEH knockout and sEH inhibition using t-AUCB
[33]. This study showed that both sEH knockout and t-
AUCB treatment prevented hyperglycaemia in type I diabetes
through enhanced islet glucose-stimulated insulin release by
the alternate pathway and decreased islet cell apoptosis [33].
Further, a recent study supports our results and hypothesis
by showing that inhibition of sEH restored glucose home-
ostasis and insulin signalling together with increased pancre-
atic islet size in a mice model of type II diabetes [34]. These
could be the same mechanisms through which t-AUCB
improved glucose and insulin abnormalities in our study.
In patients with type II diabetes mellitus, single nucleo-
tide polymorphisms in the sEH gene were associated with an
increased risk of cardiovascular disease [35] and hyperten-
sion [36]. Although it is well established that sEH inhibitors
have beneficial effects in cardiovascular diseases [19–21],
their therapeutic potential in metabolic syndrome-induced
cardiovascular changes is unknown. In the present study,
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Figure 10: Cumulative concentration-response curves for noradrenaline (a), sodium nitroprusside (b), and acetylcholine (c) in thoracic
aortic rings after 16 weeks from CS-, HCHF-, CS + t-AUCB-, HCHF + t-AUCB-treated rats. ∗P < 0.05 versus CS-fed rats; ∗∗P < 0.05 versus
HCHF-fed rats.
t-AUCB treatment attenuated the cardiovascular changes
induced by high-carbohydrate high-fat feeding including
elevated systolic blood pressure and endothelial dysfunction
fibrosis, hypertrophy, and increased stiffness in the left
ventricle of the heart. Treatment with t-AUCB also showed
improved plasma liver enzymes and decreased steatosis
compared to untreated animals.
The sEH inhibitors show target engagement in many
studies in terms of increasing the plasma concentrations of
epoxy fatty acids and decreasing the concentrations of the
corresponding diols [37]. The broad and usually beneficial
biological activities observed with the sEH inhibitors may
occur from several causes. One is that not only the 4 regioi-
somers of EETs are being stabilised but also the epoxides
of other fatty acids are being stabilised including linoleate,
eicosapentaenoic acid, and docosahexaenoic acid [38], but
the concentrations of the sometimes inflammatory diols are
being reduced [39]. Observing multiple biological effects
following the administration of a drug that influences the
arachidonate cascade is common in pharmacology with the
nonsteroidal inflammatory drugs being a case in point. Al-
though a receptor is not known for EETs, they are known
to block nuclear translocation of NFκB [40] and to down-
regulate induced iNOS and COX 2 [41], all of which
influence many downstream biological activities. Further,
the current paradigm in the origin of metabolic syndrome
is that adipocyte dysfunction promotes the metabolic and
cardiovascular symptoms of the metabolic syndrome [1,
5]. sEH activity in adipose tissue increases with adiposity
and correlates with the associated metabolic dysfunction
in obesity [29]. Thus, attenuating adiposity dysfunction by
inhibiting the increased sEH activity in adipose tissue using
t-AUCB may account for the beneficial responses seen in all
the other metabolic systems.
The sEH inhibitor, t-AUCB, like any pharmacological
probe could be producing off-target effects. However, the
low nanomolar inhibitory concentrations and picomolar Ki
of t-AUCB argue for selectivity. This class of compounds
has shown few off-target effects with most of these being in
the micromolar or nanomolar range. The same biological
responses have been observed in multiple systems using rad-
ically different sEH inhibitor structures. Although not used
in this study, the EET antagonist, 14,15-EEZE, reversed the
responses to sEH inhibitors in other models while EET
administration enhanced the responses. Some of these re-
sponses were also mimicked in rodent models of diabetes
using genetic knockouts of the sEH [34].
In summary, the present study provides new informa-
tion about the therapeutic potential of a selective sEH
inhibitor in treating the signs of diet-induced metabolic
syndrome, as well as the beneficial responses of sEH inhi-
bition on metabolic syndrome-induced cardiovascular and
liver abnormalities. The great diversity of biological effects
resulting from increased concentrations of EETs suggests
the presence of multiple receptors with the assumption
that at least some G-protein-coupled receptors are involved
[1]. Further research into identifying the receptors that
mediate EET responses in metabolically relevant tissues
would throw light on the mechanisms of action for their
therapeutic responses. sEH inhibitors also synergise the
anti-inflammatory actions of NSAIDs, which suggests that
low doses of NSAIDs could be used in combination to
reduce the symptoms of metabolic syndrome and adiposity
possibly without compromising innate immunity [1, 42].
Thus, targeting sEH with selective inhibitors either alone
or in combination with low doses of NSAIDs could reduce
metabolic and cardiovascular dysfunction in metabolic syn-
drome.
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